
VIEWPOINT

ROLE OF QUALITY ASSURANCE IN Pharmaceutical industry: A Pillar of Safety and Compliance








Introduction

The journey of a drug from discovery to patient use in the Pharmaceutical Industry is a complex and highly regulated process. Each phase spanning across research & development, manufacturing, and post-market monitoring must adhere to strict regulatory standards ensuring patient safety, data integrity, and product quality always. At the heart of this rigorous system lies Quality & Compliance, a vital mechanism that underpins the pharmaceutical industry's commitment to patient health. In this Point of View, we explore the critical role of QA ensuring Quality and Compliance throughout the drug lifecycle in Pharmaceutical Industry, highlight challenges in traditional approaches, and showcase how Generative AI (Gen AI) is revolutionizing QA practices by eliminating baseline problems & providing ground-breaking solutions to meet modern demands.


The Role of Quality Assurance in the Drug Lifecycle

Quality Assurance ensures Patient Safety, Product Quality & Data Integrity in all below stages of the Drug Lifecycle by enforcing the teams to follow processes compliant with all GxP regulations like Good Laboratory Practices, Good Clinical Practices, Good Manufacturing Practices, Good Documentation Practices etc.



Challenges in Traditional QA Approaches

Despite its importance, traditional QA methods face several challenges in today's dynamic pharmaceutical environment.



Scalability Issues with QA practices across Multilingual region



As pharmaceutical companies expand operations globally, managing & harmonizing quality across regions and languages becomes increasingly difficult. This lack of scalability hinders the uniform application of QA practices, especially in multilingual and multi-regional contexts.

E.g., A company conducting clinical trials in a multilingual region (e.g., Latin America, Southeast Asia) must ensure that all participant-facing documents are available in the local languages with same Quality standards. Miscommunication or poor-quality translations can lead to participants not fully understanding the trial, which can affect enrollment and data quality.

Challenge 04


Management of Warning Letters and Compliance Risks



Regulatory agencies issue warning letters when inspections uncover significant deficiencies in IT systems. These letters signal serious compliance risks, expensive fines, halting product approvals and requiring costly immediate remediation. Addressing warning letters demands significant resources, emphasizing the need for proactive and robust QA strategies. It underscores the pressing need for robust, proactive, and scalable QA systems.

E.g., Common findings include inadequate software validation & testing, deficient risk assessment, lack of audit trails for electronic data & deletion of audit trails, breaches in data governance & application security, substandard Change Control & CAPA, and unsatisfactory deviation management.

These challenges emphasize the importance of adopting innovative tools and approaches to ensure regulatory compliance, maintain product quality, and safeguard company reputation. QA personnel must be mindful of the challenges always and take a proactive & multifaceted approach to overcome the traditional challenges. One of the most common approaches is the QA team's tactics to unify their skills, thoughts and intelligence to maintain consistency throughout, constant oversight, remain updated always on the regulatory changes and focus being audit ready.



Enhancing QA Effectiveness using Generative AI

Generative AI is transforming traditional QA by introducing efficiency, scalability, and precision. Here are keyways it enhances QA practices:

Assist in document creation to reduce manual processes

Gen Al automates the creation of various documents standard operating procedures (SOPs), regulatory submissions, and validation protocols with same level of consistency. This reduces manual documentation, human error, accelerates documentation processes, and always ensures consistency with significant momentum.

Facilitate review processes to improve consistency

Al-powered tools analyze audit data, identify anomalies, and detect trends. These highly valuable & measurable insights enable QA teams to proactively address risks and optimize processes, ensuring compliance with minimal oversight. This gives time to QA teams to focus on high value qualitative and quantitative effort where manual intervention is expected.

Enabling easier scalability of QA practices across multilingual regions

With global drug distribution, regulatory documentation often requires translation into multiple languages and maintain uniform application of QA practices across different regions. Gen AI provides accurate, context-aware translations, simplifying communication and regulatory approval in different regions with same level of standards. This helps companies to widen their footprint globally with ease.

Real time monitoring and Data-driven Insights

IIIII

Gen AI can process vast amounts of quality data, providing predictive insights that help anticipate risks, optimize quality checks, and improve overall compliance. It can detect deviations from established procedures or compliance guidelines in real-time, allowing for immediate corrective actions. These insights enable data-driven decision-making and continuous improvement in QA & IT systems.



Regulatory Intelligence

a) Continuous Monitoring of Regulations: GenAl can be used to monitor and analyze changes in regulatory standards across different regions to ensure that processes stay up to date with the latest laws and guidelines. It can automatically integrate these changes into operational procedures, reducing the risk of non-compliance due to any outdated practices.

b) Predictive Compliance by Pattern Recognition: By analyzing regulatory trends, Al can predict potential compliance issues, future changes and suggest proactive modifications to internal compliance strategies, allowing companies to reduce the risk of non-compliance before it becomes a significant problem and to stay ahead of potential regulatory shifts.



Conclusion

Quality Assurance is the cornerstone of the pharmaceutical industry's mission to deliver safe, effective, and high-quality drugs. While traditional QA methods have served well, the increasing complexity of drug development and manufacturing poses significant challenges to maintaining compliance and operational efficiency. Generative AI is revolutionizing QA processes by addressing compliance issues through automation, precision, predictive analytics and providing actionable insights. By integrating Generative AI into compliance monitoring and streamlining routine tasks such as document creation & review, enabling multilingual translations, and regulatory intelligence, Gen AI frees QA professionals to focus on more strategic and productive activities

which include making critical quality decisions, implementing proactive risk mitigation strategies, and driving continuous improvement to ensure complete regulatory compliance. As the pharmaceutical industry adopts these advancements, QA teams will be better equipped to meet evolving regulatory demands while contributing to a more efficient and innovative healthcare system. Leveraging Gen AI in QA practices ensures not only compliance but also empowers professionals to enhance the quality and safety of life-saving medicines for patients worldwide. The ultimate result is a more robust and proactive compliance management system, which is vital for maintaining both safety and business success in the highly regulated pharmaceutical industry.

Authors:



Nitin Umapathy Kashyap Senior Consultant - Lifesciences Domain Consulting Group



Rathnakar Raghunath Principal Consultant - Lifesciences Domain Consulting Group



For more information, contact askus@infosys.com

© 2025 Infosys Limited, Bengaluru, India. All Rights Reserved. Infosys believes the information in this document is accurate as of its publication date; such information is subject to change without notice. Infosys acknowledges the proprietary rights of other companies to the trademarks, product names and such other intellectual property rights mentioned in this document. Except as expressly permitted, neither this documentation nor any part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, printing, photocopying, recording or otherwise, without the prior permission of Infosys Limited and/ or any named intellectual property rights document.

